RxDoctor Payments Data

Sultan Lakhani, MD

Geriatric Psychiatry · Richmond, VANPI 1114975471

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Sunovion Pharmaceuticals Inc. at 30.6% of the total.

$509in general payments, 2019–2025

Across 16 payments — averaging $31.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$156
  • Alkermes, Inc.$109
  • Johnson & Johnson$95
  • Lundbeck LLC$47
  • AbbVie$40
  • Vanda Pharmaceuticals Inc.$36
  • plus $26 from 2 others

What the payments were for

  • Food & beverage$509100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few geriatric psychiatry providers in Virginiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$11,906
Medicare patients
46
Services billed
161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate82$261,619
Abilify MaintenaAripiprazole38$108,846
GeodonZiprasidone Hcl26$34,352
Risperdal ConstaRisperidone Microspheres13$20,965
Aripiprazole164$19,547
Paliperidone ErPaliperidone49$12,837
Chlorpromazine Hcl41$11,014
Divalproex Sodium160$7,978
Fluphenazine Decanoate41$5,158
Olanzapine171$4,412
Haloperidol Decanoate38$4,084
Ziprasidone Hcl58$3,890
Clozapine80$3,808
Fluphenazine Hcl24$3,603
Divalproex Sodium ErDivalproex Sodium81$3,301

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$95$282,58495 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few geriatric psychiatry providers in Virginiaon file to place this against a meaningful peer group, so we don't.

Other geriatric psychiatry in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →